Evidence map›Paper›PMID 24030939›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2013

Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships.

Lynn Kane, Kelly Moore, Dieter Lütjohann, Daniel Bikle, Janice B Schwartz

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00723385 (Effects of Vitamin D on Lipids), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00723385 nacompletednot on this map

Effects of Vitamin D on Lipids

TypeinterventionalSponsorUniversity of California, San FranciscoRan2008 to 2012Enrolled130ConditionsHypercholesterolemia, Vitamin D DeficiencyArmsVitamin D (1000 or 2000 IU/day), Placebo
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?International journal of molecular sciences · 2020
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Lynn KaneMD, 302 Silver Avenue, San Francisco, CA 94112. Janice.schwartz@ucsf.edu.
Kelly Moore
Dieter Lütjohann
Daniel Bikle
Janice B Schwartz
Jewish Home · USUniversity Hospital Bonn · DEUniversity of California, San Francisco · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Vitamin D Receptor Coactivators in KeratinocytesR01AR050023 · NIAMS · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI BIKLE, DANIEL DAVID · 2004 to 2014
$3.4M
Older Persons &Drugs: race, gender, and age effectsR01AG015982 · NIA · NORTHWESTERN UNIVERSITY · PI SCHWARTZ, JANICE B · 1999 to 2009
$2.2M
Older Persons & Drugs: race, gender, and age effectsR56AG015982 · NIA · JEWISH HOME OF SAN FRANCISCO · PI SCHWARTZ, JANICE B · 2010 to 2010
$225k
NCRR NIH HHS UL1 RR024131NIAMS NIH HHS R01 AR050023NIA NIH HHS R01 AG015982NIA NIH HHS R01 AG 15982NIA NIH HHS R56 AG015982NIA NIH HHS R56 AG15982
6 · The paper itself

Abstract

contextInverse associations between 25-OH vitamin D levels and cardiovascular morbidity and mortality have been reported.

objectivesOur goals were to 1) investigate effects of correcting inadequate D status on lipids, 2) determine whether free 25-OH D is better correlated with lipids than total 25-OH D.

designA randomized, double-blind placebo-controlled trial was performed.

settingParticipants resided in the general community.

participantsAdults with inadequate D status were randomized to D3: 14 men, 12 women, age 60 ± 8 years (mean ± SD) or placebo: 12 men, 11 women: 59 ±12 years.

interventionResponses to 12-week oral vitamin D3 titrated (1000-3000 IU/d) to achieve 25-OH D levels ≥25 ng/mL were compared to placebo.

main outcome measuresMeasurements were 25-OH D (tandem mass spectometry), free 25-OH D (direct immunoassay), lipids (directly measured triglyceride, cholesterol, and subfractions; plant sterols and cholesterol synthesis precursors), and safety labs before and after 6 and 12 weeks D3 or placebo. Data were analyzed by repeated measures ANOVA and linear regression.

resultsVitamin D3 was titrated to 1000 IU/d in 15/26 (58%), to 2000 IU/d in 10, and 3000 IU/d in one patient. D3 had no effect on cholesterol or cholesterol subfractions except for trends for decreases in atorvastatin-treated patients (cholesterol, P = .08; low-density lipoprotein [LDL] cholesterol, P = .05). Decreased campesterol concentrations (P = .05) were seen with D3 but not placebo in statin-treated patients. Relationships between total 25-OH D and lipids were not detected, but inverse linear relationships were detected between free 25-OH D and triglycerides (P = .03 for all participants [n = 49], P = .03 in all statin-treated [n = 19], and P = .0009 in atorvastatin-treated [n = 11]), and between free 25-OH D and LDL cholesterol (P = .08 overall, P = .02 in all statin-treated, and P = .03 for atorvastatin-treated), and total cholesterol (P = .09 overall; P = .04 for all statin-treated, and P = .05 for atorvastatin-treated).

conclusionsVitamin D lipid-lowering effects appear limited to statin-treated patients and are likely due to decreased cholesterol absorption. Relationships between lipids and D metabolites were only detected when free 25-OH D was measured, suggesting the superiority of determining free 25-OH D levels compared to total 25-OH vitamin D levels when analyzing biologic responses.

Indexed as

Administration, OralAgedCholecalciferolDouble-Blind MethodDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasLinear ModelsLipid MetabolismLipidsMaleMiddle AgedVitamin DVitamins25-hydroxyvitamin DCholecalciferolHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsVitamin DVitamins

Identifiers

PMID24030939
PMCPMC3816263
OpenAlexW2076462603

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.